However, the approved anti-TNF therapeutic infliximab and the TNF inhibitor Lenercept failed in clinical trials with MS patients [138, 139], demonstrating that nonselective targeting of TNF is contraindicative in MS. The gene discussed is TNF; the disease is myeloid sarcoma.